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ABSTRACT
Background The COVID- 19 pandemic led to changes 
in patterns of presentation to emergency departments. 
Child health professionals were concerned that this could 
contribute to the delayed diagnosis of life- threatening 
conditions, including childhood cancer (CC) and type 
1 diabetes (T1DM). Our multicentre, UK- based service 
evaluation assessed diagnostic intervals and disease 
severity for these conditions.
Methods We collected presentation route, timing and 
disease severity for children with newly diagnosed CC 
in three principal treatment centres and T1DM in four 
centres between 1 January and 31 July 2020 and the 
corresponding period in 2019. Total diagnostic interval 
(TDI), patient interval (PI), system interval (SI) and disease 
severity across different time periods were compared.
Results For CCs and T1DM, the route to diagnosis 
and severity of illness at presentation were unchanged 
across all time periods. Diagnostic intervals for CCs during 
lockdown were comparable to that in 2019 (TDI 4.6, PI 1.1 
and SI 2.1 weeks), except for an increased PI in January–
March 2020 (median 2.7 weeks). Diagnostic intervals for 
T1DM during lockdown were similar to that in 2019 (TDI 
16 vs 15 and PI 14 vs 14 days), except for an increased PI 
in January–March 2020 (median 21 days).
Conclusions There is no evidence of diagnostic delay or 
increased illness severity for CC or T1DM, during the "rst 
phase of the pandemic across the participating centres. 
This provides reassuring data for children and families with 
these life- changing conditions.
INTRODUCTION
The UK instigated a national lockdown on 
23 March 2020 in response to the evolving 
COVID- 19 pandemic. There was an order 
to stay at home with permission to leave for 
essential purposes only. These rules were in 
place in England until the 1 June 2020 and 
Scotland until the 29 May 2020, when people 
were permitted to meet outside with up to 
six and eight people, respectively.1 However, 
in general, the lockdown restrictions in the 
early stages of the pandemic in the UK were 
very similar across all countries. Specific indi-
viduals with conditions that put them at high 
risk of serious illness from COVID- 19 were 
instructed to ‘shield’ by remaining at home 
and avoiding all face- to- face contact.2
The UK public health response to the 
COVID- 19 pandemic led to major changes 
in service utilisation of emergency depart-
ments (ED), with an observed 49% reduc-
tion in attendances in the week following the 
March 2020 announcement of lockdown.3 
More specifically, this reduction was also seen 
in children’s ED attendances in both Scot-
land and Italy.4 5 This raised concern among 
What is known about the subject?
 ► The UK public health response to the COVID- 19 pan-
demic led to signi"cant changes in emergency de-
partment attendances and urgent 2- week wait adult 
cancer referrals.
 ► Changes in the number of newly diagnosed type 1 
diabetes (T1DM) cases and higher proportions of se-
vere diabetic ketoacidosis (DKA) were also reported, 
following lockdown in the UK and other countries.
 ► Child health professionals were concerned that the 
pandemic could be associated with delayed presen-
tation of children with signi"cant illnesses.
What this study adds?
 ► The route to diagnosis and severe DKA rate for T1DM 
showed variability in the early lockdown period.
 ► Diagnostic intervals for both childhood cancer and 
T1DM during the "rst UK national lockdown were 
comparable to that in 2019, except for increased 
patient intervals in January–March 2020.
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child health professionals that the pandemic could be 
associated with delayed presentation of children with 
significant illnesses6 including life- changing childhood 
conditions such as type 1 diabetes (T1DM) and child-
hood cancer (CC). We were concerned there may have 
been an increase in delays in seeking medical advice (the 
patient interval (PI)) and/or accessing initial investiga-
tions and interventions (the system interval (SI)), leading 
to a prolongation of the total diagnostic interval (TDI).7
In the UK, 1900 children are diagnosed with cancer 
each year.8 9 The diverse and often insidious nature of 
presenting symptoms combined with the low incidence 
and lack of awareness of childhood malignancy may 
contribute to a prolongation of the TDI. Recent adult 
studies10 11 report that referrals via the urgent 2- week wait 
pathway for suspected cancer diagnoses decreased by 
84% from March to May 202011 and 60% in June 2020.10 
One study predicted a reduction of over 10% in 10- year 
survival of adults with cancer,11 while another predicted 
an excess of 1307 cancer deaths.10 The evidence is equiv-
ocal as to whether delays in time to diagnosis is associated 
with survival from CCs,11–13 however the psychological 
and economic distress on families awaiting a CC diag-
nosis should not be underestimated.12
Experience of the COVID- 19 pandemic for children 
with T1DM has been inconsistent. A survey of 53 Italian 
paediatric diabetes centres found that the number of chil-
dren with a new diagnosis of diabetes from February to 
April 2020 was 23% lower than the corresponding period 
in 2019. The survey also found the proportion of patients 
presenting with severe diabetic ketoacidosis (DKA) was 
increased.14 A 30- patient UK study reported an apparent 
increase in new- onset T1DM during the first 6 weeks of 
lockdown.15
The aim of the project was to assess any association of 
the COVID- 19 pandemic on new diagnoses of CC and 
T1DM at participating UK centres.
METHODS
Study design
We undertook a multicentre service evaluation using 
existing clinical case data assessing the route of diagnosis, 
diagnostic interval and severity of presentation.
Eligibility criteria were:
1. All children who attended three centres (the Royal 
Hospital for Sick Children (RHSC), Edinburgh, 
Leeds Teaching Hospitals NHS Trust and Nottingham 
University Hospitals (NUH) NHS Trust) and were di-
agnosed with cancer between 1 January and 30 June 
2019 and the corresponding period in 2020.
2. All children who attended four centres (the RHSC, 
Edinburgh, NUH NHS Trust, University Hospital 
Wishaw and Ninewells Hospital, Dundee) and were 
diagnosed with T1DM between 1 January and 31 July 
2019 and the corresponding period in 2020.
All centres were the central referral centres for chil-
dren within their region who received a new diagnosis of 
cancer or of T1DM.
A standard proforma (online supplemental files 1 and 
2) was used to retrospectively collect information on 
demographics, diagnosis, referral pathway and clinical 
presentation. We also collected information on whether 
patients were shielding at presentation (following 
specific government guidelines to minimise risk of SARS- 
CoV- 2 exposure for those considered clinically extremely 
vulnerable). Dates of symptom onset, first presentation 
to healthcare and final diagnosis were used to calculate 
TDI (time between symptom onset to diagnosis), PI 
(time between symptom onset to first presentation) and 
SI (time between first presentation to diagnosis).7 Data 
were collected and entered into a centralised database by 
named individuals at the participating centres. Data were 
double checked at the point of entry to the database and 
then reviewed by the database administrator. Any discrep-
ancies or queries from the database administrator were 
then highlighted and re- reviewed by the data collectors 
at each centre.
Statistical analysis
Descriptive analyses, !! test and Mann- Whitney U or 
Kruskal- Wallis tests were used to describe patterns of 
referral and illness, comparing the differences of key 
measures among different time periods (1 January"31 
March 2020 and 1 April"31 July 2020 and the corre-
sponding period in 2019). Pairwise comparisons of 
proportions were carried out using the Z test with Bonfer-
roni corrections. All analyses were performed with IBM 
SPSS V.26.0 for Windows (IBM Corp. Armonk, New York, 




There were 253 new diagnoses of CC during the study 
period (table 1). Of these, 164 (64%) were male and 
55 (22%) were from a black, Asian and minority ethnic 
(BAME) background. Patients were diagnosed at one 
of three principal treatment centres (Edinburgh=64, 
Leeds=100, Nottingham=89). There were no signifi-
cant differences in the distribution of gender, ethnic 
background or age at diagnosis between study periods 
(table 1). The proportion of tumour type in each eval-
uation period did not change. Overall, 95% (53/56) of 
patients who presented during the lockdown period were 
not shielding.
Overall, there was a 17% reduction in number of inci-
dent CC cases between 2019 (n=138) and 2020 (n=115). 
This change varied between centres (4% increase to 40% 
reduction) (figure 1).
Type 1 diabetes
There were 187 new diagnoses of T1DM during the study 
period (table 2). Of these, 90 (48%) were male and 18 (10%) 
were from a BAME background. Patients were diagnosed 
at one of the four participating centres (Edinburgh=45, 
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Dundee=30, Wishaw=53, Nottingham=59). There were 
no significant differences in gender, ethnic background 
or age at diagnosis between the study periods (table 2). 
Overall, 91% (42/46) of those who presented during the 
lockdown period were not shielding.
A reduction in the numbers of new cases of T1DM 
between the months of April and July 2020 and the iden-
tical period in 2019 occurred in three of the four units. 
Overall, there was a 3%–24% reduction in new diagnoses 
of T1DM between the months of January and July 2020 




Across all time points, 60% of children (152/253) were 
diagnosed within three or fewer healthcare contacts, 
25% within four to six contacts, 8% within seven to 
nine contacts and 6% required more than 10 contacts 
prior to diagnosis. There was no significant difference 
in distribution across three time periods (p=0.569) or 
January–March 2020 and April–June 2020 (p=0.359) 
(online supplemental figure S1a). General practice was 
the first point of healthcare contact in about half of the 
patients across all time periods (54% in 2019, 49% in 
January–March 2020, 48% in April–June 2020) (online 
supplemental figure S1b). Overall, 63% of patients 
presented to hospital as an emergency presentation 
either from primary care or to the ED. Overall, 36% of 
children had their diagnostic investigation requested as 
an inpatient. These proportions were consistent across 
all three time periods (p=0.405) (online supplemental 
figure S1c).










valuen Col% n Col% n Col% n Col%
Gender 0.150
  Male 162 64% 81 59% 41 69% 40 71%
  Female 91 36% 57 41% 18 31% 16 29%
Age (years) 0.963
  Under 5 99 39% 53 38% 25 43% 21 38%
  5–11 92 37% 52 38% 19 33% 21 38%
  12+ 61 24% 33 24% 14 24% 14 25%
BAME background 0.945
  No 198 78% 107 78% 47 80% 44 79%
  Yes 55 22% 31 22% 12 20% 12 21%
COVID- 19 isolation/shielding
  No 250 99% 138 100% 59 100% 53 95%
  Yes 3 1% 0 0% 0 0% 3 5%
Tumour type 0.273
  Leukaemia 69 27% 33 24% 17 29% 19 34%
  CNS tumour 74 29% 48 35% 14 24% 12 21%
  All other tumour types 110 43% 57 41% 28 47% 25 45%
ICU stay 0.275
  No 223 88% 120 87% 55 93% 48 86%
  Yes 26 10% 17 12% 3 5% 6 11%
  Not known 4 2% 1 1% 1 2% 2 4%
HCP visits before diagnosis 0.569
  3 or less 152 60% 82 59% 40 68% 30 54%
  4–6 64 25% 38 28% 12 20% 14 25%
  7–9 21 8% 11 8% 3 5% 7 13%
  10 or more 16 6% 7 5% 4 7% 5 9%
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Figure 1 Number of newly diagnosed of childhood cancer and type 1 diabetes (T1DM) cases between January and July 2020 
compared with the corresponding period in 2019. (A, C) Data covers all participating centres contributing data to the project by 
month. Shaded areas indicate national lockdown months. (B, D) Data by individual centre over the periods January–June/July 
in 2019 and 2020.
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Type 1 diabetes
The source of referral leading to diagnosis was the ED in 
30% (14/46) of cases between April and July 2020. This 
compared with 12% (5/43) of cases diagnosed between 
January and March 2020 (p=0.091) and 19% (19/98) 
of cases diagnosed over the period of January–July 2019 
(p=0.426). Overall, 63% of patients had been referred by 
their General Practitioner (GP) between April and July 
2020, compared with 81% of patients in the preceding 




Across all three centres, there was no significant differ-
ence in the distribution of TDI between 2019 (median 4.5, 
IQR 2.3–10.9 weeks) and January–March 2020 (median 
5.6, IQR 3.4–15.3 weeks) or April–June 2020 (median 
4.6, IQR 2.7–11.9 weeks) (p=0.351) (figure 2 and online 
supplemental figure S3a). There was a significant increase 
in PI between 2019 and January–March 2020 (median 0.9, 
IQR 0.1–2.1 vs median 2.7, IQR 0.7–4.4 weeks, p=0.005), 
but during April–June 2020 there was no significant 
difference compared with 2019 (median 1.1, IQR 0.3–4.7 
vs median 0.9, IQR 0.1–2.1 weeks, p=0.383) (figure 2). SI 
was stable across all time points (figure 2). The pattern 
remained the same when the 2019 data were further split 
into January–March and April–June (online supplemental 
figure S5). Differences in PI across four time periods was 
significant (p=0.011) and pairwise comparisons showed 
that PI in January–March 2020 was significantly higher 
than that in the January–March 2019 (median 2.7, IQR 
0.7–4.4 vs median 0.6, IQR 2.0 weeks, p=0.008).









p valuen Col% n Col% n Col% n Col%
Gender 0.718
  Male 90 48% 46 47% 23 53% 21 46%
  Female 97 52% 52 53% 20 47% 25 54%
Age (years) 0.174
  Under 5 32 17% 22 22% 5 12% 5 11%
  5–11 87 47% 43 44% 18 42% 26 57%
  12+ 68 36% 33 34% 20 47% 15 33%
BAME background 0.484
  No 168 90% 87 89% 41 95% 40 89%
  Yes 18 10% 11 11% 2 5% 5 11%
COVID- 19 isolation/shielding 0.012
  No 183 98% 98 100% 43 100% 42 91%
  Yes—self- isolation 3 2% 0 0% 0 0% 3 7%
  Yes—shielding 1 1% 0 0% 0 0% 1 2%
Diabetic ketoacidosis 0.624
  No 112 60% 59 61% 26 60% 27 59%
  Mild/Moderate 46 25% 25 26% 12 28% 9 20%
  Severe 28 15% 13 13% 5 12% 10 22%
Ventilation 0.607
  No 182 97% 94 96% 43 100% 45 98%
  Yes 5 3% 4 4% 0 0% 1 2%
ICU stay 0.625
  No 169 91% 90 92% 39 93% 40 87%
  Yes 17 9% 8 8% 3 7% 6 13%
HCP visits before diagnosis 0.673
  1 164 92% 87 92% 37 95% 40 89%
  >1 15 8% 8 8% 2 5% 5 11%
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There was no significant difference in TDI across all 
time periods for leukaemias, CNS tumours and solid 
tumours in subgroup analyses (figure 3). There was no 
significant difference in PI or SI for individual principal 
treatment centres or tumour types (figure 3 and online 
supplemental figure S3b,c).
Type 1 diabetes
Median TDIs for incident T1DM cases were 16 (IQR 
8–28), 21 (IQR 14–32) and 15 (7–22) days for 2019, 
January–March 2020 and April–July 2020, respectively. 
There was no significant difference across the three time 
periods (p=0.119). A similar pattern was observed in PI. 
The comparison across all time periods was not signif-
icant (p=0.054), subanalyses showed that PI was longer 
during January–March 2020 compared with April–July 
2020 (median 21, IQR 14–32 vs median 14, IQR 7–22 
days, p=0.025) and 2019 (median 14, IQR 7–28 days, 
p=0.036) (figure 4 and online supplemental figure S4).
When the 2019 data were further split into January–
March and April–June, differences in PI across four time 
periods became significant (p=0.041) and none of the 
post hoc pairwise comparisons reached significant level 
(online supplemental figure S6).
Severity of presentation
Childhood cancer
Within 7 days of diagnosis, 10% (26/253) of patients with 
CC required admission to paediatric intensive care. This 
was stable across all time periods (p=0.275) (table 1).
Type 1 diabetes
The proportion of patients presenting in DKA was 41% 
(19/46) in the period April–July 2020, 40% (17/43) for 
the time period January–March 2020 and 39% (38/98) 
for the time between January and July 2019. There was 
no significant difference in the proportion of patients 
in DKA across all time periods. The proportion of chil-
dren presenting with severe DKA (pH <7.1, serum 
bicarbonate <5 mmol/L)16 showed no statistical differ-
ence between lockdown April–July 2020 (22%, 10/46) 
compared with 12% (5/43) January–March 2020 and 
13% (13/98) January–July 2019) in the periods prior to 
lockdown (p=0.447). There was no significant difference 
in the rate of intensive care admission or requirement for 
ventilatory support (table 2).
DISCUSSION
We have demonstrated that the first phase of the 
COVID- 19 pandemic was not associated with route of 
presentation, TDI or disease severity at presentation for 
children with a new diagnosis of CC or T1DM at the study 
centres. Given the reported reduction in paediatric ED 
attendance,17 18 it had been predicted that both the PI 
and TDI would be prolonged and clinical presentations 
would be more severe. This prediction was not supported 
by our study.
A snapshot survey was commissioned in April 2020 by 
the Child Cancer Smart Team in conjunction with the 
Childhood Cancer and Leukaemia Group (CCLG) to 
obtain the absolute numbers of new diagnoses of CC 
at each principal treatment centre in the UK (online 
supplemental file 3). This survey revealed 27% fewer new 
cases in April 2020 compared with April 2019, raising 
concerns about the potential for diagnostic delay. Similar 
anxieties had been expressed related to delayed presen-
tation of patients with T1DM.19 One survey of diabetes 
units in the UK reported that 20% of children and young 
people diagnosed with T1DM between 1 March and 30 
June 2020 had had a delayed presentation. Reasons for 
this included fear of contracting SARS- CoV- 2 as well as 
limited access to GP services.15
Similarities between type 1 diabetes and childhood cancer 
presentations
While T1DM and CC cancer are different in terms of 
their presentations, we chose to investigate them together 
because they are both relatively rare, yet well recognised 
and potentially life- threatening conditions. We found no 
evidence that either of these conditions were associated 
Figure 2 Time to diagnosis for childhood cancer. (A) Total diagnostic interval (TDI): interval between !rst symptom onset to 
diagnosis. (B) Patient interval (PI): time from initial symptom onset to !rst presentation to healthcare. (C) System interval (SI): 
time between !rst presentation to healthcare to diagnosis.
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Figure 3 Time to diagnosis for childhood cancer for leukaemia, CNS (Central Nervous System) tumour and all other tumour 
types combined. (A) Total diagnostic interval (TDI): interval between !rst symptom onset to diagnosis. (B) Patient interval (PI): 
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with delayed presentations associated with the pandemic. 
Other similarities include a higher PI during January–
March 2020 and a shift from presentation via the general 
practitioner to the emergency department.
We demonstrated higher PI during January–March 
2020 for patients with CC and T1DM. This may reflect a 
period of uncertainty for patients and healthcare systems 
in preparation for the first phase of the pandemic. There 
was widespread UK media coverage of the approaching 
pandemic and we hypothesise that this may have resulted 
in families initially avoiding healthcare services. Further 
work will be required to establish whether this hypothesis 
can be substantiated with evidence from the behaviour 
and beliefs of service users themselves. The subsequent 
reduction in PI during and after lockdown suggests no 
significant delay in caregivers seeking medical attention 
for children, which may reflect increased public health 
messaging that was not initially present during the lead 
up to lockdown and the pandemic.
While there was variability between units, there was 
evidence of a shift towards first presentations to ED from 
primary care, for patients with CC and T1DM. While 
we did not identify statistically significant changes, we 
recommend that each treatment centre evaluate any 
change in how their services have been accessed during 
the pandemic, to assist in future service planning.
Type 1 diabetes
A study of the North- West London Paediatric Diabetes 
Network between 23 March and 4 June 2020 reported an 
apparent increase in cases of new- onset T1DM in two of 
the five units.15 Overall, 21/30 children with a new diag-
nosis presented with DKA, 52% of which were severe. 
These are generally considered to represent high rates of 
both of DKA and severe DKA in newly diagnosed patients. 
However, the number of children involved in this study 
was small, no comparisons were possible with other time 
periods and we were unable to replicate the findings.
In a large survey of 53 Italian paediatric diabetes centres, 
the number of newly diagnosed children with T1DM and 
DKA were similar to 2019.14 However, the proportion of 
all patients with T1DM who developed severe DKA was 
significantly greater in 2020 (44.3% vs 36.1%, p=0.03).14 
Despite not being significant, the pattern of our results 
are similar to the Italian experience14 which demon-
strated a 9% reduction in new diagnoses of T1DM when 
comparing January–July 2020 to January–July 2019. Our 
data showed a 7%–44% reduction in 3 of the 4 months 
following lockdown in new cases of T1DM, with a 27% 
decrease during March 2020 when national lockdown 
was announced. The incidence of DKA at presentation 
was stable between the measured time periods, however 
the incidence of severe DKA was slightly worse following 
lockdown (22% (April–July 2020) vs 12% (January–
March 2020) vs 13% (January–July 2019)).
The increased incidence of severe DKA among patients 
diagnosed post lockdown, while not significant, is a 
concern. This finding is consistent with the Italian data 
and with other units in the UK.14 19 It initially appears 
to be counterintuitive when one takes into account the 
reduction in the TDI and PI post lockdown. However, 
it is well recognised that some children with T1DM can 
present acutely with rapid onset of ketoacidosis. The 
increased rate of severe DKA at presentation serves to 
emphasise the importance of the ongoing provision of 
public health campaigns to raise awareness of the symp-
toms of T1DM among parents/caregivers.20
Childhood cancer
Overall, TDI for CCs was stable between the three time 
periods. Consistent with previously published evidence,13 
the TDI for leukaemia was shorter than for CNS tumours, 
Figure 4 Time to diagnosis of incident T1DM cases between January and July 2020 and corresponding period in 2019. 
(A) Total diagnostic interval (TDI): interval between !rst symptom onset to diagnosis. (B) Patient interval (PI): time from initial 
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suggesting that the COVID- 19 pandemic did not disturb 
this pattern.
A large cross- sectional survey from the Paediatric 
Oncology East and Mediterranean Group reported that 
some centres noticed that all newly diagnosed patients 
experienced delays in diagnosis during the pandemic.21 
This was thought to be due to: (1) patients refusing to 
present for essential visits for fear of contracting COVID- 
19; (2) hospital staff being relocated to other areas and 
(3) governmental decisions affecting the availability of 
public transport and freedom of travel. Although in the 
UK during the first lockdown the availability of public 
transport was decreased and in some tertiary oncology 
centres paediatric hospital staff were redeployed, our 
data does not support a similar situation in the partici-
pating centres.
Overall, 10% of new CC diagnoses in this study 
required intensive care within 7 days of admission, the 
majority of these had CNS tumours, most likely due to 
the requirement for early neurosurgery. From this we 
infer that patients diagnosed during the pandemic were 
not more unwell than if they had been diagnosed earlier. 
We recognise that intensive care admission resulting from 
treatment can occur in the early stages post diagnosis.22 
Consequently, using intensive care admission may overes-
timate initial disease severity. Reassuringly, a CCLG Study 
reported that children with cancer and SARS- CoV- 2 
infection do not appear at increased risk of severe infec-
tion compared with the general paediatric population.23
Study limitations
Only four UK centres were involved, therefore the study 
lacked the ability to detect national variations in patterns 
of presentation. Given the retrospective nature of our 
study, we cannot exclude the possibility of incomplete 
areas of data collection, since that some of the chil-
dren in the service evaluation will have been treated 
in more than one centre. We believe that this effect is 
both random and minimal across the centres. Our data 
collection approaches used a standardised electronic 
form replicated across all centres. Data were entered by 
individuals at each centre and double checked by the 
same individual at the point of entry to the database. 
Data were subsequently assessed and cleaned by the data-
base administrator and any discrepancies or queries were 
sent back to the individual who had collected the data 
for resolution. With more resource we would have used 
double data entry techniques and the fact that we were 
unable to do this represents a limitation of our study.
Given the resources available for this service evaluation, 
we elected to collect comparison data for 1 year prior to 
the pandemic (2019). However, we recognise that fluc-
tuation occurs and a longer period of prepandemic data 
collection would have provided greater insight into this 
variation. It was reassuring however that the incident 
cases of CC across the UK as a whole remained stable 
from 2013 to 2017.24
In view of the fluid situation of the pandemic, data 
collection was completed in July 2020 as we believed that 
timely presentation could inform local practice. We will 
continue data collection to account for the diagnostic lag 
for specific diseases including brain tumours. Data collec-
tion at a more comprehensive national level would also 
provide greater clarity on diagnostic intervals. Further-
more, it is important to establish whether subsequent 
public health measures are associated with longer time to 
diagnosis due to an evolving backlog of patient referrals 
across the UK.
CONCLUSIONS
This project was born out of a desire to understand the 
diagnostic intervals and severity of two life- changing child-
hood diagnoses during the COVID- 19 pandemic. Our 
findings suggest that public health measures, imposed 
to control the spread of the pandemic during the first 
lockdown in the UK, were not associated with delayed 
diagnosis of CC or T1DM at participating centres. This 
is good news in the context of a pandemic that has been 
harmful to children’s health and well- being in many 
other ways. We believe that our study can play a key role 
in allaying parental and professional concern.
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